GT Biopharma, Inc. reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
San Francisco, CA
SEC filing record 1 source field available
Fiscal year end
31 December
GT Biopharma, Inc. has filed 875 SEC EDGAR filings since 12 May 1995

SEC filing history

Showing 176-200 of 516 matching filings.

Per page
25
Current page
8
4

PRIMARY DOCUMENT

Filing date
14 Feb 2022
Reporting date
31 Dec 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

FORM 3

Filing date
14 Feb 2022
Reporting date
11 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
3

PRIMARY DOCUMENT

Filing date
14 Feb 2022
Reporting date
28 Nov 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

PRIMARY DOCUMENT

Filing date
14 Feb 2022
Reporting date
13 Jan 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-32837

SC 13G/A filing

Filing date
28 Jan 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
UPLOAD

UPLOAD filing

Filing date
26 Jan 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SC 13G/A File 005-32837

AMENDMENT NO. 6 TO SCHEDULE 13G

Filing date
18 Jan 2022
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
CORRESP

CORRESP filing

Filing date
29 Dec 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q/A File 001-40023

PRIMARY DOCUMENT

Filing date
29 Dec 2021
Reporting date
30 Jun 2021
Next action
Verify source filing
8-K File 001-40023

PRIMARY DOCUMENT

Filing date
23 Dec 2021
Reporting date
22 Dec 2021
Next action
Verify source filing
8-K File 001-40023

PRIMARY DOCUMENT

Filing date
21 Dec 2021
Reporting date
15 Dec 2021
Next action
Verify source filing
UPLOAD

UPLOAD filing

Filing date
15 Dec 2021
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-40023

PRIMARY DOCUMENT

Filing date
26 Nov 2021
Reporting date
23 Nov 2021
Next action
Verify source filing
4

PRIMARY DOCUMENT

Filing date
12 Nov 2021
Reporting date
16 Feb 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
3

PRIMARY DOCUMENT

Filing date
12 Nov 2021
Reporting date
13 Jan 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-40023

PRIMARY DOCUMENT

Filing date
01 Nov 2021
Reporting date
01 Nov 2021
Next action
Verify source filing
4

FORM 4

Filing date
07 Oct 2021
Reporting date
16 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
3

PRIMARY DOCUMENT

Filing date
07 Oct 2021
Reporting date
11 Nov 2020
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-40023

CURRENT REPORT

Filing date
23 Sep 2021
Reporting date
17 Sep 2021
Next action
Verify source filing
8-K File 001-40023

CURRENT REPORT

Filing date
13 Sep 2021
Reporting date
13 Sep 2021
Next action
Verify source filing
NT 10-Q File 001-40023

NT 10-Q

Filing date
17 Aug 2021
Reporting date
30 Jun 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
8-K File 001-40023

CURRENT REPORT

Filing date
19 May 2021
Reporting date
19 May 2021
SEC evidence
Open document Open filing
Next action
Verify source filing
10-Q File 001-40023

QUARTERLY REPORT

Filing date
17 May 2021
Reporting date
31 Mar 2021
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .